Related Experiment Video

Updated: May 11, 2026

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis
08:55

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis

Published on: August 7, 2018

FLIP: molecular switch between apoptosis and necroptosis

JingJing Gong1, Saikartik A Kumar, Gilian Graham

  • 1Department of Urology, School of Medicine, South Texas Veterans Health Affairs System, The University of Texas Health Science Center, San Antonio, Texas.

Molecular Carcinogenesis
|April 30, 2013
PubMed

Insights

Targeting multiple cancer pathways simultaneously is crucial for effective treatment. This review explores targeting FLIP (Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein) signaling to bridge programmed cell death (PCD) pathways for improved cancer management.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Cancer's complexity necessitates multi-targeted therapies due to diverse causes and resistance mechanisms.
  • Targeting single pathways often yields limited clinical benefits, highlighting the need for broader strategies.
  • Programmed cell death (PCD) pathways (apoptosis, necroptosis, autophagy) are critical in tumor suppression but involve complex signaling networks.

Purpose of the Study:

  • To review the potential of targeting FLIP (Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein) signaling.
  • To highlight FLIP as a central modulator bridging various PCD pathways for cancer therapy.
  • To propose FLIP-targeted strategies for overcoming therapeutic resistance and improving cancer management.

Main Methods:

  • Literature review of studies on cancer signaling pathways and programmed cell death.
  • Analysis of the role of FLIP in regulating apoptosis, necroptosis, and autophagy.
  • Examination of FLIP's potential as a therapeutic target in various cancers.

Main Results:

  • FLIP acts as a key regulator and integrator of multiple PCD pathways.
  • Dysregulation of FLIP is implicated in the progression and resistance of various cancers.
  • Targeting FLIP offers a strategy to simultaneously engage multiple cell death mechanisms.

Conclusions:

  • FLIP signaling represents a promising convergence point for developing novel, multi-targeted cancer therapies.
  • Modulating FLIP could enhance the efficacy of existing treatments and overcome therapeutic resistance.
  • Further research into FLIP-centric strategies is warranted for advancing cancer management.
Keywords:
FLIPapoptosisautophagynecroptosisprogrammed cell death

More Related Videos

Evaluation of Caspase Activation to Assess Innate Immune Cell Death10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

Related Concept Videos

Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized by phagocytes.
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...